Motley Fool points to retatrutide's Phase 3 results, up to 28.3% average weight loss, and Lilly's plan to file for FDA approval in early 2027.
Recap by typeshit. Full story at AOL.com.
Lilly's tirzepatide shot Zepbound now has FDA approval in a KwikPen format for weight management. Tap through for details on the new pen.
At the SIO congress in Palermo, specialists flagged short real-world adherence and no national reimbursement in Italy. Oral semaglutide and orforglipron are expected there in 2027.
Polish pharmacy platform GdziePoLek says, citing the manufacturer, that the first Oral Wegovy shipment should arrive soon. No exact launch date is set yet.
A short clip from Dr. Reese pushing back on the rush toward peptides as an easy shortcut, with little detail beyond that.
Pooling 37 phase 3 trials and over 50,000 adults, researchers found each point of weight lost tracked with about 0.37 mmHg lower systolic pressure.
The post says four in ten patients drop GLP-1 drugs within a year over side effects, and pharma is turning to amylin-based shots as the next step.
Loading…